VOR vs ILMN

Illumina, Inc.

(ILMN) offers the better valuation at 30. 5x trailing P/E (31. 8x forward), making it the more compelling value choice. Analysts rate Vor Biopharma Inc. (VOR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Illumina, Inc.

(ILMN) delivered a total return of -62. 3%, compared to -96. 7% for Vor Biopharma Inc. (VOR). Over 10 years, the gap is even starker: ILMN returned +22. 4% versus VOR's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 04β versus Vor Biopharma Inc. 's 1. 90β — meaning VOR is approximately 82% more volatile than ILMN relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Illumina, Inc.

grew EPS 170. 9% year-over-year, compared to -107. 4% for Vor Biopharma Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus 0. 0% for Vor Biopharma Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus 0. 0% for VOR. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VOR: 124.

8% to $31. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04)). Vor Biopharma Inc. (VOR) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +22. 4%, VOR: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.